Compass Pathways (NASDAQ:CMPS) Stock Rating Reaffirmed as Buy by BTIG Research

Compass Pathways (CMPS) Q3 2026 Earnings Call Transcript

COMP360 targets first-half 2027 launch with $444M cash backing regulatory approval.

Compass Pathways (NASDAQ:CMPS) Stock Rating Reaffirmed as Buy by BTIG Research

BTIG Research reiterated a "buy" rating and issued a $25.00 target price on shares of Compass Pathways in a report on Tuesday.

COMPASS Pathways stock rebounds after earnings (CMPS:NASDAQ)

Compass Pathways (CMPS) stock rebounds after Q3 results calm launch fears over psilocybin compound COMP360 as Usona completes FDA filings first. Read more here.

Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona

This morning, Compass Pathways shared its Q3 2026 results, which included an update on its COMP360 psilocybin for treatment-resistant depression (TRD) new drug application (NDA) submission. “Final NDA submission nearing completion”, the first bullet point in the release states, “and will be filed in the next two weeks.” “With the imminent completion of our NDA […]

Compass Pathways reports US$444M cash and 2028 runway

Compass Pathways reports US$444 million in cash, funding operations into 2028, as it targets its final psilocybin application submission in November.

Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights – Novumpr

Final NDA submission nearing completion and will be filed in the next two weeks Launch readiness on track for expected launch in H12027, subject to FDA approval Data from two positive Phase 3 trials reinforce COMP360’s unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 […]